MaRS Innovation Announces New Strategic Partnership with Pfizer

TORONTO, April 22, 2013 /CNW/ - MaRS Innovation, a Centre of Excellence for 
Commercialization and Research, today announced the formation of a strategic 
partnership with Pfizer Inc. to advance early-stage technologies related to 
human health in therapeutics and diagnostics. 
Through this collaboration, MaRS Innovation and Pfizer will jointly identify 
investment opportunities emerging from well-validated scientific research 
discoveries within MaRS Innovation's 16 member institutions, including the 
University of Toronto and its nine affiliated teaching hospitals. 
"There's growing consensus that transferring technologies from the university 
lab bench and into the market requires unique public-private partnerships," 
said Dr. Raphael Hofstein, president and CEO of MaRS Innovation. "Partnering 
with MaRS Innovation gives Pfizer access to Toronto's robust innovation 
pipeline and a close look at emerging IP from Canada. It signals both the 
strength and attractiveness of our commercialization model and Toronto-based 
research technologies to global industry players." 
"Our government is committed to making Ontario the best place to translate 
great ideas into innovative products that will gain demand around the world," 
said the Honourable Reza Moridi, Ontario Minister of Research and 
Innovation."Today's announcement from MaRS Innovation is an exciting 
collaboration with Pfizer that will both advance healthcare technologies for 
Ontarians and help to strengthen our economy." 
Pfizer will provide funding over a three-year period to support promising 
individual projects based on their due diligence, which will be leveraged with 
financial support from MaRS Innovation. Together, it is intended to accelerate 
the development and validation of healthcare technologies within a highly 
innovative academic cluster in Canada. 
"We are excited by this partnership with MaRS Innovation and look forward to 
working collaboratively to help advance promising healthcare technologies," 
said Uwe Schoenbeck, chief scientific officer, External R&D Innovation at 
Pfizer. 
The partnership's shared vision for transformative technologies will benefit 
the health of Canadians and others around the world. "Forming this partnership 
also builds on MaRS Innovation's recent success in securing $15 million in 
funding from the Networks of Centres of Excellence," said Hofstein. "Pfizer is 
a significant global player in delivering healthcare technologies in Canada 
and worldwide; our projects will benefit from their understanding of the 
marketplace and help us achieve our goal of jointly developing long-term, 
mutually-beneficial technological solutions to many challenging health 
problems." 
About MaRS Innovation  MaRS Innovation is the commercialization agent for 
Ontario's exceptional discovery pipeline from 16 leading academic 
institutions. As a single-entry point to member-based activity of $1 billion 
in annual research and development, MI is a gateway for investors and 
licensees to access technology assets. Supported by the Government of Canada 
through the Networks of Centres of Excellence, by the Government of Ontario 
through the Ontario Centres of Excellence, and by its 16 member institutions, 
MI is a transformational partnership that turns research strengths into 
commercial opportunities. MI's portfolio includes the most promising assets 
from its members' pipeline, which it advances into global markets through 
industry partnerships, licensing and company creation. 
Media Contact Elizabeth Monier-Williams Marketing and Communications Manager 
MaRS Innovation 647-537-9097 emonierwilliams@marsinnovation.com @marsinnovation 
SOURCE: MaRS Innovation 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/April2013/22/c7057.html 
CO: MaRS Innovation
ST: Ontario
NI: BTC VNT  
-0- Apr/22/2013 13:05 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.